The upper endoscopy procedures using Pure-Vu Gastro were found to be highly efficient for first-time users. Credit: amab / Shutterstock.com.

Motus GI and the Ecuadorian Institute of Digestive Diseases (IECED) have completed the initial clinical assessment of the Pure-Vu Gen 4 Gastro device for upper gastrointestinal (GI) bleeding procedures.

The initial clinical evaluation demonstrated that the Pure-Vu Gen 4 Gastro device significantly navigates and evaluates the upper GI tract. It received high usability scores, ranging from very good to excellent.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The upper GI tract procedures proved highly efficient for first-time users, with an average duration of just 11 minutes.

In the colon, the evaluation demonstrated an improvement in the average Boston Bowel Prep Scale for nine patients from 5.9 to 8.9 using Pure-Vu, with an average procedure time of 24 minutes.

The company is in the process of submitting a 510(k) application to the US Food and Drug Administration for the Pure-Vu Gen 4 Gastro device in the fourth quarter of this year.

Roughly 400,000 upper GI bleed cases were reported in the US in 2019.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Motus GI CEO Mark Pomeranz said: “The focus of these procedures was aimed at evaluating the device’s ability to improve a physician’s visualisation while identifying and treating upper GI bleeds.”

Further assessments of the Pure-Vu Gen 4 system will study its effectiveness in essential areas such as upper GI bleeding and explore novel therapeutic uses, including underwater endoscopic mucosal resection.

The Pure-Vu Gen 4 Gastro takes advantage of the colon device’s successful pulsed vortex irrigation and smart sense suction methods.

This upgraded version includes enhancements to target and address blood and blood clots in the upper GI tract.

Furthermore, the system has undergone additional enhancements to facilitate easy navigation within the GI tract. It also allows the physician to hold the endoscope, thereby minimising any ergonomic challenges typically encountered during the procedure.

The company is deploying the Gen 4 technology to optimise the capabilities of the Pure-Vu device within the colon.

The Pure-Vu Gen 4 Gastro and Colon systems will use the same workstation to enhance visualisation in both the upper and lower GI tract to enable the use of these systems across various indications.